Delcath Systems (OTC:DCTH) last week said that it closed a $20 million private placement round for the liver cancer treatment it developed.
The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant another share, also at 6¢ apiece.
Get the full story on our sister site, Drug Delivery Business.